What does apheresis — costs incurred, net of reversals mean?

This metric represents the net operational expenses specifically attributed to the Apheresis business unit, adjusted for any reversals of previously accrued costs. It reflects the underlying cost structure of the segment after accounting for reversals of prior period provisions or accruals. Monitoring this helps investors understand the true recurring cost burden of the Apheresis operations.

Haemonetics (HAE) Apheresis — Costs incurred, net of reversals

Screener

Other segment segments

MedSurg

$2.31M—

Corporate

-$24K—

Similar metrics at other companies

PGFABRIC & HOME CARE — Cost incurred

$6M-71.4%

PGBABY, FEMININE & FAMILY CARE — Cost incurred

$10M-20.0%

XPO

XPOEuropean Transportation — Charges Incurred

$4M-55.6%

XPO

XPONorth American LTL — Charges Incurred

$1M0.0%

XPO

XPONorth American Intermodal Operation — Charges Incurred

$0—

FLSFCD — Charges, net of adjustments

$22.76M+749%

Other financials

Income statement

See full

Revenue$339.4M+5.6%

Gross profit$202.8M+5.5%

Operating income$57.5M+6.7%

Net income$33.0M-3.0%

EPS (diluted)$0.72+2.9%

Balance sheet

See full

Cash & equivalents$223.4M-23.7%

Total debt$1.2B-4.1%

Total equity$837.1M-5.1%

Total assets$2.4B-3.9%

Cash flow

See full

Operating cash flow$52.3M+201%

CapEx$7.9M+111%

Free cash flow$44.4M+226%

Valuation

See full

Market cap$3.87B+6.3%

Enterprise value$4.82B+5.4%

P/E25.7×-10.5×

P/S2.9×+0.2×

Profitability

See full

Gross margin59%+2.1pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin21.5%+7.5pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.4×0.0×

Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:RestructuringCharges.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 6:09 AM EDT
Fiscal quarter: Q1 FY2027
Calendar quarter: Q2 2026
Accession: 0000313143-26-000120

Line item	Three Months Ended / June 27, 2026	Three Months Ended / June 28, 2025
Restructuring costs
Apheresis	$13	$(452)
MedSurg	2,309	576
Corporate	(24)	1,142
Total	$2,298	$1,266
Restructuring related costs
Apheresis	—	$9
MedSurg	—	—

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's apheresis — costs incurred, net of reversals?: Haemonetics (HAE) reported apheresis — costs incurred, net of reversals of $13K in Q2 2026.
What does apheresis — costs incurred, net of reversals mean?: This metric represents the net operational expenses specifically attributed to the Apheresis business unit, adjusted for any reversals of previously accrued costs. It reflects the underlying cost structure of the segment after accounting for reversals of prior period provisions or accruals. Monitoring this helps investors understand the true recurring cost burden of the Apheresis operations.